This suggests that the role of ETV5 in bladder carcinogenesis may not be limited to FGFR3-mutant tumours but may also be relevant to tumours with other alterations resulting in MAPK/ERK activation, such as RAS mutations. This evidence concerns the gene ETV5 and neoplasm.